Key result
Cisplatin-based chemotherapy linked to extensive acute arterial thrombosis in a lung cancer case report.
Why the study?
Arterial thrombosis during adjuvant cisplatin-based chemotherapy for completely resected lung cancer is extremely rare and not well characterized.
Case Report (n=1)
No
Cisplatin-based chemotherapy can induce severe adverse vascular effects, including acute arterial thrombosis, even in the absence of a primary malignant tumor.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to arterial thrombosis risk during cisplatin chemotherapy for lung cancer; leaves open need for prospective thromboprophylaxis studies.
A malignant tumor can cause hypercoagulation and it also often coexists with thrombosis. Cisplatin-based chemotherapy can also induce adverse vascular effects, including arterial thrombosis. We herein report a case of acute arterial thrombosis in a patient undergoing postoperative adjuvant cisplatin-based chemotherapy for completely resected lung cancer. The patient complained of acute leg pain after chemotherapy, and computed tomography revealed multiple thrombi from the thoracic to popliteal arteries. Arterial thrombosis during adjuvant chemotherapy is extremely rare; however, careful clinical observation of patients receiving cisplatin-based chemotherapy is important, because arterial thrombosis, even in the absence of the primary malignant tumor, is possible.
No takes yet. Share an insight, caveat, or question.
Sato et al. (2017) conducted a case report in Completely resected lung adenocarcinoma (n=1). Cisplatin-based chemotherapy was evaluated on Acute arterial thrombosis. A 68-year-old man developed acute arterial thrombosis extending from the thoracic to popliteal arteries on day 13 of postoperative adjuvant cisplatin-based chemotherapy for resected lung cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: